Abstract：
Adenoviral vectors are crucial for gene therapy and vaccine development, offering a platform for gene delivery into host cells. Since the discovery of adenoviruses, first-generation vectors with limited capacity have evolved to third-generation vectors flacking viral coding sequences, balancing safety and gene-carrying capacity. The applications of adenoviral vectors for gene therapy and anti-viral treatments have expanded through the use of in vitro ligation and homologous recombination, along with gene editing advancements such as CRISPR-Cas9. Current research aims to maintain the efficacy and safety of adenoviral vectors by addressing challenges such as pre-existing immunity against adenoviral vectors and developing new adenoviral vectors from rare adenovirus types and non-human species. In summary, adenoviral vectors have great potential in gene therapy and vaccine development. Through continuous research and technological advancements, these vectors are expected to lead to the development of safer and more effective treatments.
摘要：
腺病毒载体对于基因治疗和疫苗开发至关重要。为基因传递到宿主细胞提供了一个平台。自从发现腺病毒以来,能力有限的第一代载体已经进化到缺失病毒编码序列的第三代载体，平衡安全性和基因携带能力。通过使用体外连接和同源重组，腺病毒载体在基因治疗和抗病毒治疗中的应用得到了扩展，随着基因编辑的进步，如CRISPR-Cas9。当前的研究旨在通过解决诸如针对腺病毒载体的预先存在的免疫力以及从稀有腺病毒类型和非人类物种开发新的腺病毒载体等挑战来维持腺病毒载体的功效和安全性。总之,腺病毒载体在基因治疗和疫苗开发中具有巨大的潜力。通过不断的研究和技术进步，这些载体有望导致开发更安全、更有效的治疗方法。
